文献速递前列腺癌

转移性去势抵抗性前列腺癌治疗毒性的群体分析

Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study.
PubMed 文献 · Urology · 2017-11-27

本研究基于加拿大安大略省2003至2015年2439例≥65岁mCRPC男性的回顾性队列,评估阿比特龙、恩扎卢胺、多西他赛和卡巴他赛的毒性及有效性。阿比特龙和恩扎卢胺暴露与任何原因或治疗相关毒性无关;多西他赛暴露与任何原因(HR 1.29)和治疗相关(HR 1.52)毒性风险增加相关;卡巴他赛暴露与治疗相关毒性风险显著相关(HR 5.94),但与任何原因毒性无关。

要点

  • 阿比特龙和恩扎卢胺未显示与任何原因或治疗相关毒性风险增加相关。
  • 多西他赛暴露与任何原因(HR 1.29)和治疗相关(HR 1.52)毒性风险增加相关。
  • 卡巴他赛暴露与治疗相关毒性风险显著相关(HR 5.94),但与任何原因毒性无关。

核心结论

  • 在mCRPC患者中,阿比特龙或恩扎卢胺未显示与治疗相关并发症导致的住院和急诊就诊风险增加相关;而静脉化疗药物与这些并发症导致的住院和急诊就诊风险增加相关。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入2003至2015年加拿大安大略省2439例年龄≥65岁、接受阿比特龙、恩扎卢胺、多西他赛或卡巴他赛治疗的mCRPC男性。

主要发现

  • 阿比特龙暴露与任何原因毒性(P = .19)和治疗相关毒性(P = .45)均无关。
  • 恩扎卢胺暴露与任何原因毒性(P = .52)和治疗相关毒性(P = .64)均无关。
  • 多西他赛暴露与任何原因毒性风险增加相关(HR 1.29,95%CI 1.15-1.44)。
  • 多西他赛暴露与治疗相关毒性风险增加相关(HR 1.52,95%CI 1.33-1.74)。
  • 卡巴他赛暴露与治疗相关毒性风险显著相关(HR 5.94,95%CI 1.87-18.92),但与任何原因毒性无关(HR 2.37,95%CI 0.59-9.63)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the toxicity and effectiveness of contemporary metastatic castrate-resistant prostate cancer (mCRPC) treatments at a population level, among all patients in Ontario particularly treated with newer agents, including abiraterone, enzalutamide, docetaxel, and cabazitaxel. METHODS: We performed a population-based, retrospective cohort study of 2439 men aged ≥65 years treated for mCRPC with abiraterone, enzalutamide, docetaxel, or cabazitaxel from 2003 to 2015 in Ontario, Canada. Our primary outcome was treatment-related toxicity, defined as hospitalizations and emergency room (ER) visits during mCRPC treatment. Based on toxicity profiles identified during phase III trials, we further identified specific treatment-related toxicity. We calculated hazard ratios (HRs) using multivariable Cox proportional hazards models with time-varying exposures. RESULTS: Abiraterone and enzalutamide exposure were not associated with any-cause (P = .19 and .52, respectively) or treatment-related (P = .45 and .64, respectively) toxicities. In contrast, docetaxel exposure was associated with an increased risk of any-cause (HR 1.29, 95% confidence interval [CI] 1.15-1.44) and treatment-related (HR 1.52, 95% CI 1.33-1.74) toxicities. Cabazitaxel exposure was associated with a significant risk of treatment-related toxicity (HR 5.94, 95% CI 1.87-18.92) but not any-cause toxicity (HR 2.37, 95% CI 0.59-9.63). CONCLUSION: Among patients with mCRPC, we failed to show any increased risk of hospitalizations and ER visits for treatment-related complications for abiraterone or enzalutamide. In contrast, treatment with intravenous chemotherapeutic agents was associated with an increased risk of hospitalizations and ER visits to manage these complications.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Wallis CJD, Satkunasivam R, Saskin R, et al. Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study. Urology. 2017. PMID: 29191639. doi:10.1016/j.urology.2017.08.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。